BMFTR

BMF Therapeutics is a clinical-stage biotechnology company focused on developing novel covalent small molecule therapies for metabolic diseases and orphan cancers. The company utilizes its proprietary COVALENT platform to design highly selective and irreversible inhibitors of high-impact biological targets. Its lead candidate, BMF-219, is a first-in-class covalent Menin inhibitor currently being evaluated in clinical trials for the treatment of Type 2 Diabetes and various liquid and solid tumors. BMF Therapeutics aims to provide long-term disease modification by restoring physiological function in metabolic disorders and inducing potent anti-tumor responses in oncology. The company is also advancing BMF-500, a covalent FLT3 inhibitor, for the treatment of acute myeloid leukemia. Headquartered in Newport Beach, California, BMF Therapeutics is led by an experienced team of drug hunters and supported by prominent life science investors.